Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16316790 | 0.85 | SMN1; SMN2 (0.65) | MAOBSMN1; SMN2ENPP2KMT2ACAPN1 | |
| SCHEMBL4072806 | 0.85 | MAOB (0.53) | MAOBTRPV4APPESR1ESR2 | |
| SCHEMBL27844647 | 0.83 | MAOB (0.52) | MAOBTRPV4APPESR1ESR2 | |
| SCHEMBL27938722 | 0.83 | MAOB (0.52) | MAOBTRPV4APPESR1ESR2 | |
| SCHEMBL25316225 | 0.79 | ENPP2 (0.37) | MAOBSMN1; SMN2ESR1ESR2ENPP2 | |
| SCHEMBL30507069 | 0.79 | ENPP2 (0.37) | MAOBSMN1; SMN2ESR1ESR2ENPP2 | |
| Formaldehyde SCHEMBL28968600 | 0.79 | ESR1 (0.45) | MAOBSMN1; SMN2ESR1ESR2HSP90AA1 | |
| SCHEMBL2719702 | 0.78 | CA12 (0.54) | SMN1; SMN2TRPV4CYP3A4GAA | |
| SCHEMBL12888826 | 0.78 | MCOLN3 (0.57) | SMN1; SMN2TRPV4CYP3A4MEN1KMT2A | |
| SCHEMBL11143856 | 0.78 | MAOB (0.46) | MAOBSMN1; SMN2TRPV4APPESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1530470-B9 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7585977-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1530470-B1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | DALLY ROBERT DEAN | 2008-09-04 | — | — | US | disclosed |
| US-7399867-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7169499-B2 | Sulfonated polyphosphazenes, uses thereof, and methods for preparing same | PARALLEL SOLUTIONS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | GPER1, ESR2, ESR1 | MAOB 1455/4885SMN1; SMN2 4010/4885TRPV4 509/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | MAOB 1455/4885SMN1; SMN2 4010/4885TRPV4 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.